Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
1.25
-0.01 (-0.79%)
At close: May 15, 2025, 12:32 PM
-0.79% (1D)
| Bid | 1.25 |
| Market Cap | 44.98M |
| Revenue (ttm) | 726.33K |
| Net Income (ttm) | -15.09B |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -0.59 |
| Analyst | Buy |
| Ask | 1.29 |
| Volume | 45,692 |
| Avg. Volume (20D) | 192,245 |
| Open | 1.25 |
| Previous Close | 1.26 |
| Day's Range | 1.24 - 1.28 |
| 52-Week Range | 1.00 - 3.83 |
| Beta | -0.23 |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+9.09%
Immuneering shares are trading higher. Needham rei...
Unlock content with
Pro Subscription
4 months ago
+0%
Immuneering shares are trading higher after the company released interim data from its Phase 2a trials of IMM-1-104 and IMM-6-415 in advanced RAS and RAF-mutant tumors.
